Effect of additive calcium administration on FGF23 levels in patients with mild chronic kidney disease treated with calcitriol: A randomized, open-labeled clinical trial
Therapeutics and Clinical Risk Management Aug 21, 2017
Han N, et al. – In this assessment, the clinicians explored the effect of additional calcium carbonate treatment on fibroblast growth factor 23 (FGF23) levels in patients treated with calcitriol. Their investigations displayed that additional calcium carbonate treatment significantly increased serum FGF23 levels in patients treated with calcitriol, with their synergistic effect in promoting intestinal calcium absorption. Therefore, serum FGF23 levels should be monitored regularly, especially in those who use the combination of vitamin D and calcium carbonate from the early stages of chronic kidney disease (CKD).
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries